Anti-BC200 RNA Autoantibodies in Systemic Lupus Erythematosus
Provides a novel approach for the development of lupus treatments based on anti-BC abs.
Background:
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting an estimated 1.5 million Americans. Between 50% to 90% of lupus patients will develop neuropsychiatric SLE (NPSLE) during their lifetimes, with neurological manifestations...
Published: 12/7/2023
|
Inventor(s): Henri Tiedge, Anna Iacoangeli
Keywords(s):
Category(s): Campus > SUNY Downstate Health Sciences University
|
Treatment of Neuropsychiatric Lupus
Directly targets autoimmune antibodies that cause lupus-related seizures and cognitive impairment. Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder with poorly understood etiology and no significantly effective treatment. The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million...
Published: 7/11/2023
|
Inventor(s): Henri Tiedge, Ilham Muslimov, Ellen Ginzler
Keywords(s): lupus, regulatory RNAs, seizures, Technologies
Category(s): Campus > SUNY Downstate Health Sciences University, Technology Classifications > Therapeutics and Vaccines
|
Cancer Blood Testing Using BC200 RNA Isolated from Peripherial Blood for Diagnosis and Treatment of Invasive Breast Cancer
Kits can be developed to facilitate the isolation and characterization of circulating tumor cells expressing these breast cancer small RNAs. Background: Breast cancer remains a leading cause of death from malignancies in women, despite the fact that early detection via mammography and improved therapeutic intervention have resulted in a decrease of...
Published: 7/11/2023
|
Inventor(s): Henri Tiedge, Anna Iacoangeli
Keywords(s): TAF, Technologies
Category(s): Campus > SUNY Downstate Health Sciences University, Technology Classifications > Diagnostics, Technology Classifications > Biomedical Science and Engineering, Technology Classifications > Healthcare
|
Molecular Diagnosis and Prognosis of Carcinomas
A novel molecular marker that provides a reliable prognostic indicator for DCIS breast cancer patients.
Background:
Ductal carcinoma in situ (DCIS) is non-invasive type of breast cancer that occurs in the milk ducts, accounting for approximately 20% of new breast cancers. DCIS is non-invasive and not life-threatening. However, patients diagnosed...
Published: 7/11/2023
|
Inventor(s): Henri Tiedge
Keywords(s): breast cancer, Technologies
Category(s): Technology Classifications > Screens and Assays, Technology Classifications > Diagnostics, Campus > SUNY Downstate Health Sciences University
|